0001415889-24-002017.txt : 20240130 0001415889-24-002017.hdr.sgml : 20240130 20240130210140 ACCESSION NUMBER: 0001415889-24-002017 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240124 FILED AS OF DATE: 20240130 DATE AS OF CHANGE: 20240130 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Moshkevich Solomon CENTRAL INDEX KEY: 0002010019 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37478 FILM NUMBER: 24580368 MAIL ADDRESS: STREET 1: C/O NATERA, INC. STREET 2: 13011 MCCALLEN PASS, BLDG A, SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78753 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Natera, Inc. CENTRAL INDEX KEY: 0001604821 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 010894487 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 13011 MCCALLEN PASS STREET 2: BUILDING A SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78753 BUSINESS PHONE: 650-249-9090 MAIL ADDRESS: STREET 1: 13011 MCCALLEN PASS STREET 2: BUILDING A SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78753 3 1 form3-01312024_020132.xml X0206 3 2024-01-24 0 0001604821 Natera, Inc. NTRA 0002010019 Moshkevich Solomon C/O NATERA, INC. 13011 MCCALLEN PASS BUILDING A SUITE 100 AUSTIN TX 78753 false true false false President, ClinicalDiagnostics Common Stock 167051 D Stock Option (right to buy) 7.4491 2025-03-25 Common Stock 5752 D Stock Option (right to buy) 12.8501 2025-06-17 Common Stock 3323 D Stock Option (right to buy) 9.59 2026-04-07 Common Stock 27501 D Stock Option (right to buy) 10.41 2027-06-08 Common Stock 42500 D Stock Option (right to buy) 9.29 2028-03-08 Common Stock 20000 D Stock Option (right to buy) 15.57 2029-03-07 Common Stock 5932 D Stock Option (right to buy) 19.68 2029-03-21 Common Stock 34000 D Includes (a) 82,816 shares of common stock held by the Reporting Person, (b) 1,375 shares subject to the Reporting Person's March 27, 2020 restricted stock unit ("RSU") grant that will vest in successive equal quarterly installments through March 27, 2024, (c) 2,004 shares subject to the Reporting Person's January 22, 2021 RSU grant that will vest in successive equal quarterly installments through January 21, 2025, (d) 4,566 shares subject to the Reporting Person's January 28, 2022 RSU grant that will vest in successive equal quarterly installments through January 20, 2026, (continued from footnote 1) (e) 9,619 shares subject to the Reporting Person's June 10, 2022 RSU grant that will vest in successive equal annual installments through May 25, 2026, (f) 37,248 shares subject to the Reporting Person's January 27, 2023 RSU grant that will vest in successive equal quarterly installments through January 27, 2027, and (g) 29,423 shares subject to the Reporting Person's August 25, 2023 RSU grant that will vest full on September 1, 2026. The vesting of all such RSU grants is subject to the Reporting Person's continuous Service (as defined in the Issuer's Equity Incentive Plan, (the "2015 EIP")) through each such date and subject to acceleration as provided in the 2015 EIP. The options are fully vested. /s/ Tami Chen, Attorney-in-Fact 2024-01-30 EX-24 2 ex24-01312024_020132.htm ex24-01312024_020132.htm


POWER OF ATTORNEY


The undersigned, as a Section 16 reporting person of Natera, Inc. (the “Company”), hereby constitutes and appoints each of the persons listed on Exhibit A attached hereto, the undersigned’s true and lawful attorney-in-fact to:


1.

complete and execute Form ID and Forms 3, 4, and 5 and other forms and all amendments thereto as such attorney-in-fact shall in his or her discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company; and


2.

do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national association, the Company and such other person or agency as the attorney-in-fact shall deem appropriate.


The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with the Securities Exchange Act of 1934 (as amended).


This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.    


IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 25th day of January, 2024.




Signature:

/s/ Solomon Moshkevich

Name:  

Solomon Moshkevich




GDSVF&H\



EXHIBIT A


Daniel Rabinowitz

Tami Chen

Vincent Fontanilla

Jeffrey Thacker



GDSVF&H\